Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01581307 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01581307 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT01581307, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and impact on survival with treatment with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) as second-line treatment with in patients gemcitabine-refractory metastatic pancreatic cancer with predominantly liver metastases.
Interventions
- DRUG FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)
- DEVICE TheraSpheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01581307
The ClinicalTrials.gov registry entry for NCT01581307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) is the first listed.
NCT01581307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01581307 about?
NCT01581307 is a clinical study titled "Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets". The purpose of this study is to evaluate the safety and impact on survival with treatment with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) as second-line treatment with in patients gemcitabine-refractory metastatic pancreatic cancer with pre...
What is the current status of trial NCT01581307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-04. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01581307?
The interventions under investigation include: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) (DRUG), TheraSpheres (DEVICE).
Who is sponsoring clinical trial NCT01581307?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.